Since its identification,[9] different potent GnRH agonists have been developed, including goserelin acetate.[10] The efficacy of GnRH agonists was confirmed in early-stage breast cancer as adjuvant therapy[11] and as a therapy for prostate carcinoma. Here, GNRH1 is linked to breast carcinoma.